Brain-computer interface (BCI) maker Subsense announced today that it emerged from stealth mode with $17 million in seed financing.
Covina, California–based Subsense develops a non-surgical, nanoparticle-based BCI. Golden Falcon Capital led its seed funding round.
The company collaborates with UC Santa Cruz and ETH Zurich to develop a safe, effective and accessible BCI. They aim for the system to enhance lives and redefine the interaction between human cognition and technology.
“Brain-computer interfacing promises to unlock limitless human potential, but innovation has been held back by a lack of effective non-surgical approaches,” said Tetiana Aleksandrova, Subsense CEO. “By delivering nanoparticles that bind with receptors in the brain, Subsense can achieve more extensive connectivity with a far gentler approach.”
According to the company’s website, it targets those with paralysis and neurological disorders with its BCI. The company’s biocompatible nanoparticles integrate with the brain for safety and compatibility. At the core of the BCI, they help to accurately record and stimulate brain activity without adverse effects, Subsense says.
The company is developing therapeutics for patients with neurological conditions such as Parkinson’s, Alzheimer’s, epilepsy, depression, strokes, chronic pain and more.
Its BCI technology delivers targeted stimulation to specific brain regions, aiming to restore motor functions and enhance rehabilitation therapies. Subsense believes the BCI could help users control smartphones and navigate complex machinery. Its real-time brain monitoring capabilities could also provide critical data to aid in the early detection and understanding of neurological conditions. That could lead to more accurate diagnoses, better-informed treatment plans and a deeper understanding of brain health.
Other potential target areas include recovery of vision, hearing and movement, as well as inner speech decoding and thought translation. Subsense hopes to integrate the BCI with AI and work on mental health regulation and appetite control.
